Therapeutic agent

Pyridostigmine

PreliminaryEvidence level
1Registered trials
3Conditions
0Study references

Evidence Summary

Evidence Level
Preliminary
Mechanism
Enrollment: Estimated, Sponsor Type: Other, Unknown / General
Safety
Cholinergic side effects (GI cramping, diarrhea, salivation, sweating, bradycardia). Avoid in asthma, mechanical obstruction. Overdose risk cholinergic crisis.
Dosing
30–60 mg TID (sometimes 30 mg); titrate; study durations often 4–8 weeks for hemodynamic assessment.
Crossover RCT + review supports hemodynamic benefit, esp hyperadrenergic POTS. 30-60mg TID. Cholinergic SE dose-limiting. Reasonable targeted option.

Clinical Trials

1 trial(s) registered

NCT IDTitlePhaseStatus
NCT06366724LIFT: Life Improvement TrialPhase 2Recruiting

Key Studies / References

  • See linked studies